BillionToOne study finds Northstar Response tissue-free ctDNA assay matches or beats tumor-informed monitoring in advanced cancer patients

PUBT · 2d ago
BillionToOne study finds Northstar Response tissue-free ctDNA assay matches or beats tumor-informed monitoring in advanced cancer patients
  • BillionToOne reported peer-reviewed real-world study results comparing Northstar Response with a tumor-informed ctDNA monitoring test in advanced cancer.
  • Findings were published in The Journal of Liquid Biopsy; no future presentation was disclosed.
  • Northstar Response tracked treatment-related disease changes as well as, or better than, the tumor-informed approach.
  • In cases where the tests disagreed, Northstar Response aligned with imaging or biopsy, pointing to errors in the comparator results.
  • Results support a tissue-free workflow that can broaden access to monitoring when tumor tissue is unavailable or delays testing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Billiontoone Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070700PRIMZONEFULLFEED9841158) on October 07, 2026, and is solely responsible for the information contained therein.